Tirzepatide side effects: what 160,620 FDA adverse event reports show
Drug class
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist, GLP-1 Receptor Agonist
Brand names
Mounjaro
Who reports
160,620 reports · 18% serious · 889 with death outcome · 76% female
Used for
MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor.
What it is
MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains amino.
Boxed warning
RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO ca.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug titration issue | 52 | 316.4 190.6–525.3ROR 316.5 · calibrated p 8e-11 ✓ | 88.8 EB05 70.4 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=18 · 81% consumer | not reported in cached trials |
| Intercepted product selection error | 553 | 102.9 92.0–115.0ROR 103.2 · calibrated p 1e-7 ✓ | 57.3 EB05 53.4 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | 98% consumer | not reported in cached trials |
| Injection site coldness | 303 | 74.3 64.5–85.6ROR 74.5 · calibrated p 1e-6 ✓ | 47.2 EB05 42.9 · IC025 +5.3 3/3 methods agree | Labeled (related wording) related wording | 98% consumer | not reported in cached trials |
| Therapeutic response changed | 2,231 | 72.9 69.2–76.8ROR 73.9 · calibrated p 1e-6 ✓ | 46.8 EB05 45.2 · IC025 +5.5 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Intercepted product dispensing error | 563 | 69.3 62.6–76.8ROR 69.6 · calibrated p 2e-6 ✓ | 45.2 EB05 42.2 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | 96% consumer | not reported in cached trials |
| Accidental underdose | 4,609 | 60.3 58.3–62.5ROR 62.1 · calibrated p 3e-6 ✓ | 41.3 EB05 40.3 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=25 · 98% consumer | not reported in cached trials |
| Starvation ketoacidosis | 54 | 51.9 37.8–71.2ROR 51.9 · calibrated p 2e-5 ✓ | 36.8 EB05 29.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=54 | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Injection site injury | 1,463 | 47.3 44.6–50.3ROR 47.8 · calibrated p 2e-5 ✓ | 34.8 EB05 33.3 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious n=12 · 97% consumer | NCT04255433: 2/6,647 (0.0%) on Tirzepatide (serious AE) |
| Product tampering | 465 | 45.5 40.9–50.5ROR 45.6 · calibrated p 2e-5 ✓ | 33.8 EB05 31.3 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=58 · 94% consumer | not reported in cached trials |
| Extra dose administered | 9,608 | 41.3 40.3–42.2ROR 43.8 · calibrated p 3e-5 ✓ | 31.4 EB05 30.9 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | age-adj. PRR 59.5 · serious n=142 · 97% consumer | not reported in cached trials |
| Gastric hypomotility | 57 | 30.1 22.6–40.2ROR 30.1 · calibrated p 3e-4 ✓ | 24.4 EB05 19.5 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=54 · 100% consumer | not reported in cached trials |
| Injection site hypersensitivity | 548 | 28.2 25.7–30.9ROR 28.3 · calibrated p 4e-4 ✓ | 23.2 EB05 21.7 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=43 · 92% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Gastrointestinal hypomotility | 367 | 25.6 22.9–28.6ROR 25.6 · calibrated p 6e-4 ✓ | 21.4 EB05 19.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=348 · 95% consumer | NCT04184622: 1/636 (0.2%) on Tirzepatide (serious AE) |
| Obstructive pancreatitis | 118 | 24.8 20.4–30.3ROR 24.9 · calibrated p 8e-4 ✓ | 20.9 EB05 17.9 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=118 · 75% consumer | NCT04255433: 6/6,647 (0.1%) on Tirzepatide (serious AE) |
| Eructation (belching) | 2,913 | 23.5 22.6–24.4ROR 23.9 · calibrated p 8e-4 ✓ | 20.0 EB05 19.4 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious n=332 · 96% consumer | NCT04255433: 359/6,647 (5.4%) on Tirzepatide |
| Allodynia | 154 | 20.6 17.4–24.4ROR 20.6 · calibrated p 0.002 ✓ | 17.8 EB05 15.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=50 · 88% consumer | not reported in cached trials |
| Incorrect dose administered | 29,672 | 19.7 19.5–19.9ROR 24.0 · calibrated p 8e-4 ✓ | 17.2 EB05 17.1 · IC025 +4.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 26.1 · serious PRR 2.4 · 97% consumer | not reported in cached trials |
| Hunger | 1,772 | 19.7 18.7–20.7ROR 19.9 · calibrated p 0.002 ✓ | 17.2 EB05 16.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=49 · 98% consumer | not reported in cached trials |
| Impaired gastric emptying | 1,678 | 19.7 18.7–20.7ROR 19.9 · calibrated p 0.002 ✓ | 17.2 EB05 16.5 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious PRR 50.7 · 92% consumer | NCT04255433: 5/6,647 (0.1%) on Tirzepatide (serious AE) |
| Intercepted product prescribing error | 170 | 19.6 16.7–23.0ROR 19.6 · calibrated p 0.002 ✓ | 17.1 EB05 15.0 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | 95% consumer | not reported in cached trials |
| Food craving | 638 | 19.2 17.6–20.8ROR 19.2 · calibrated p 0.002 ✓ | 16.8 EB05 15.7 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=28 · 96% consumer | not reported in cached trials |
| Skin laxity | 47 | 16.8 12.4–22.7ROR 16.8 · calibrated p 0.005 ✓ | 14.8 EB05 11.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | ♀ 100% (drug 76%) · 100% consumer | not reported in cached trials |
| Acute cholecystitis necrotic | 21 | 16.6 10.5–26.1ROR 16.6 · calibrated p 0.007 ✓ | 14.2 EB05 9.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=21 · 71% consumer | NCT04255433: 2/6,647 (0.0%) on Tirzepatide (serious AE) |
| Injection site paraesthesia | 165 | 15.9 13.6–18.7ROR 16.0 · calibrated p 0.006 ✓ | 14.2 EB05 12.5 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | 97% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Incorrect product dosage form administered | 44 | 15.9 11.6–21.8ROR 15.9 · calibrated p 0.007 ✓ | 14.1 EB05 10.8 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Medullary thyroid cancer | 34 | 14.6 10.2–20.8ROR 14.6 · calibrated p 0.010 ✓ | 12.8 EB05 9.4 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | serious n=32 · 74% consumer | NCT04255433: 2/6,647 (0.0%) on Tirzepatide (serious AE) |
| Lack of satiety | 24 | 13.9 9.1–21.2ROR 13.9 · calibrated p 0.013 ✓ | 12.0 EB05 8.1 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Duodenogastric reflux | 24 | 12.6 8.3–19.1ROR 12.6 · calibrated p 0.018 ✓ | 10.8 EB05 7.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=15 · 83% consumer | not reported in cached trials |
| Product administered at inappropriate site | 1,256 | 9.6 9.1–10.2ROR 9.7 · calibrated p 0.036 ✓ | 9.0 EB05 8.6 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 15.6 · serious n=16 · 94% consumer | not reported in cached trials |
| Injection site haemorrhage | 5,281 | 9.2 9.0–9.5ROR 9.5 · calibrated p 0.038 ✓ | 8.7 EB05 8.5 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 9.7 · serious PRR 2.5 · 97% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Increased appetite | 1,113 | 8.2 7.7–8.7ROR 8.2 · calibrated p 0.062 | 7.7 EB05 7.3 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 9.3 · serious PRR 3.8 · 95% consumer | NCT04255433: 3/6,647 (0.0%) on Tirzepatide (serious AE) |
| Injection site pustule | 22 | 8.0 5.2–12.3ROR 8.0 · calibrated p 0.079 | 6.7 EB05 4.6 · IC025 +2.0 3/3 methods agree | Labeled (related wording) related wording | 100% consumer | not reported in cached trials |
| Injection site rash | 1,728 | 7.8 7.5–8.2ROR 7.9 · calibrated p 0.069 | 7.4 EB05 7.1 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 6.0 · serious n=94 · 89% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Accidental overdose | 2,060 | 7.7 7.4–8.1ROR 7.8 · calibrated p 0.071 | 7.3 EB05 7.1 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 10.3 · serious PRR 0.6 · 97% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Injury associated with device | 1,133 | 7.7 7.3–8.2ROR 7.8 · calibrated p 0.072 | 7.3 EB05 7.0 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 9.7 · 94% consumer | not reported in cached trials |
| Vomiting projectile | 161 | 7.7 6.6–9.1ROR 7.7 · calibrated p 0.075 | 7.2 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=82 · 95% consumer | not reported in cached trials |
| Injection site hypoaesthesia | 79 | 7.7 6.1–9.6ROR 7.7 · calibrated p 0.079 | 7.1 EB05 5.8 · IC025 +2.4 3/3 methods agree | Labeled (related wording) related wording | 100% consumer | NCT04255433: 2/6,647 (0.0%) on Tirzepatide (serious AE) |
| Incorrect product formulation administered | 47 | 7.7 5.7–10.3ROR 7.7 · calibrated p 0.082 | 6.9 EB05 5.4 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | 85% consumer | not reported in cached trials |
| Glycosylated haemoglobin abnormal | 65 | 7.5 5.9–9.7ROR 7.5 · calibrated p 0.084 | 6.9 EB05 5.6 · IC025 +2.4 3/3 methods agree | Lab value / disease marker | serious n=11 · 91% consumer | NCT04255433: 4/6,647 (0.1%) on Tirzepatide (serious AE) |
| Sleep disorder due to general medical condition, insomnia type | 344 | 7.3 6.6–8.2ROR 7.3 · calibrated p 0.087 | 6.9 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=74 · 96% consumer | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Pancreatitis | 1,901 | 3.13.0–3.3 | signal |
| Hypoglycaemia | 1,881 | 2.62.5–2.7 | signal |
| Hyperglycaemia / diabetes | 3,416 | 1.31.2–1.3 | raised |
| Depression | 1,951 | 0.90.9–0.9 | lower than other drugs |
| Anaphylaxis / angioedema | 529 | 0.50.5–0.6 | lower than other drugs |
| Liver injury | 882 | 0.40.4–0.4 | lower than other drugs |
| Kidney injury | 1,132 | 0.30.3–0.3 | lower than other drugs |
| Arrhythmia / qt | 418 | 0.30.3–0.3 | lower than other drugs |
| Tendon disorder | 80 | 0.30.2–0.3 | lower than other drugs |
| Suicidality | 514 | 0.30.2–0.3 | lower than other drugs |
| Venous thromboembolism | 452 | 0.30.2–0.3 | lower than other drugs |
| Opportunistic infection | 264 | 0.30.2–0.3 | lower than other drugs |
| Gi bleeding | 345 | 0.20.2–0.3 | lower than other drugs |
| Fall / fracture | 680 | 0.20.2–0.2 | lower than other drugs |
| Hyponatraemia | 131 | 0.20.2–0.3 | lower than other drugs |
| Serious infection | 1,221 | 0.20.2–0.2 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Tirzepatide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (16 of 40 signal terms matched).
- NCT04255433 — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants Wi (N=13299, PHASE3; 1556 AE terms posted; arms: Tirzepatide (MTD); 1.5 mg Dulaglutide)
- NCT04184622 — A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (N=2539, PHASE3; 193 AE terms posted; arms: Placebo; 5 mg Tirzepatide; 10 mg Tirzepatide; 15 mg Tirzepatide)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Incorrect dose administered | 29,672 | 19.7 19.5–19.9ROR 24.0 · calibrated p 8e-4 ✓ | 17.2 EB05 17.1 · IC025 +4.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 26.1 · serious PRR 2.4 · 97% consumer | not reported in cached trials |
| Nausea | 17,092 | 2.9 2.8–2.9ROR 3.1 · calibrated p 0.597 | 2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 3.4 · 93% consumer | NCT04255433: 5/6,647 (0.1%) on Tirzepatide (serious AE) |
| Injection site pain (pain where injected) | 13,906 | 6.2 6.1–6.3ROR 6.7 · calibrated p 0.111 | 6.0 EB05 5.9 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 6.9 · serious PRR 2.0 · 96% consumer | NCT04255433: 8/6,647 (0.1%) on Tirzepatide (serious AE) |
| Diarrhoea (diarrhea) | 10,006 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.994 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 3.2 · 92% consumer | NCT04255433: 13/6,647 (0.2%) on Tirzepatide (serious AE) |
| Extra dose administered | 9,608 | 41.3 40.3–42.2ROR 43.8 · calibrated p 3e-5 ✓ | 31.4 EB05 30.9 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | age-adj. PRR 59.5 · serious n=142 · 97% consumer | not reported in cached trials |
| Off label use (used outside approved label) | 8,941 | 1.3 1.3–1.4ROR 1.4 · calibrated p 0.554 | 1.3 EB05 1.3 · IC025 +0.4 | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 1.4 · 92% consumer | not reported in cached trials |
| Vomiting | 8,267 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.858 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 4.3 · 90% consumer | NCT04255433: 20/6,647 (0.3%) on Tirzepatide (serious AE) |
| Drug ineffective (drug did not work) | 6,965 | 0.7 0.7–0.7ROR 0.7 · calibrated p 0.118 | 0.7 EB05 0.7 · IC025 -0.6 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 0.4 · 94% consumer | not reported in cached trials |
| Constipation | 6,502 | 4.0 3.9–4.1ROR 4.1 · calibrated p 0.352 | 3.9 EB05 3.8 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.6 · serious PRR 5.3 · 95% consumer | NCT04255433: 8/6,647 (0.1%) on Tirzepatide (serious AE) |
| Injection site haemorrhage | 5,281 | 9.2 9.0–9.5ROR 9.5 · calibrated p 0.038 ✓ | 8.7 EB05 8.5 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 9.7 · serious PRR 2.5 · 97% consumer | NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE) |
| Injection site erythema (redness where injected) | 5,210 | 5.7 5.6–5.9ROR 5.9 · calibrated p 0.159 | 5.5 EB05 5.4 · IC025 +2.4 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 5.2 · serious PRR 3.0 · 94% consumer | not reported in cached trials |
| Fatigue (tiredness) | 4,771 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.180 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Not in label — unassessed | age-adj. PRR 0.7 · serious PRR 1.2 · 93% consumer | NCT04255433: 4/6,647 (0.1%) on Tirzepatide (serious AE) |
| Accidental underdose | 4,609 | 60.3 58.3–62.5ROR 62.1 · calibrated p 3e-6 ✓ | 41.3 EB05 40.3 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=25 · 98% consumer | not reported in cached trials |
| Product dose omission issue | 4,474 | 2.1 2.0–2.1ROR 2.1 · calibrated p 0.997 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 2.7 · serious PRR 2.1 · 94% consumer | not reported in cached trials |
| Abdominal pain upper | 3,709 | 2.4 2.3–2.5ROR 2.4 · calibrated p 0.850 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 2.0 · serious PRR 3.8 · 95% consumer | NCT04255433: 8/6,647 (0.1%) on Tirzepatide (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Drug titration issue — n=52, PRR 316.4
- Intercepted product selection error — n=553, PRR 102.9
- Intercepted product dispensing error — n=563, PRR 69.3
- Accidental underdose — n=4,609, PRR 60.3
- Starvation ketoacidosis — n=54, PRR 51.9 (also seen in trial arm)
- Extra dose administered — n=9,608, PRR 41.3
- Gastric hypomotility — n=57, PRR 30.1
- Gastrointestinal hypomotility — n=367, PRR 25.6 (also seen in trial arm)
- Obstructive pancreatitis — n=118, PRR 24.8 (also seen in trial arm)
- Allodynia — n=154, PRR 20.6
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Tirzepatide?
In FDA FAERS, the most frequently co-reported reaction terms for Tirzepatide are nausea, injection site pain, diarrhoea, extra dose administered, vomiting, constipation. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Tirzepatide have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO ca.
Do FAERS signals prove that Tirzepatide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0818426a-53eb-4db7-9609-bbae1e7a3964, effective 20260729; matched on
openfda.generic_name.exact:"TIRZEPATIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,171 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
TIRZEPATIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.